The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for
potential therapeutic repurposing for non‐oncological indications. Considering (a) the …

Long-term potentiation (LTP) of synaptic transmission is a form of activity-dependent
synaptic plasticity that exists at most synapses in the nervous system. In the central nervous …

Abstract Poly (ADP-ribose) polymerase 1 (PARP1) is a first responder that recognizes DNA
damage and facilitates its repair. Neurodegenerative diseases, characterized by progressive …

Pyroptosis is a type of cell death that is caspase-1 (Casp-1) dependent, which leads to a
rapid cell lysis, and it is linked to the inflammasome. We recently showed that pyroptotic cell …

Epidemiology has shown that fluoride exposure is associated with the occurrence of
diabetes. However, whether fluoride affects diabetic encephalopathy is unclear. Elderly …

Inhibitors of the nuclear DNA damage sensor and signalling enzyme poly (ADP-ribose)
polymerase (PARP) have recently been introduced in the therapy of cancers deficient in …

Metachromatic leukodystrophy (MLD) is a severe demyelinating, autosomal recessive
genetic leukodystrophy, with no curative treatment. The disease is underpinned by …

Olaparib was the first poly (ADP-ribose) polymerase inhibitor approved by Food and Drug
Administration for oncology treatment. However, its neuroprotective effects have not been …

Following mild traumatic brain injury (mTBI), the ionic homeostasis of the central nervous
system (CNS) becomes imbalanced. Excess Ca2+ influx into cells triggers molecular …

Ionotropic glutamate receptors (AMPA, NMDA, and kainate receptors) play a central role in
excitatory glutamatergic signaling throughout the brain. As a result, functional changes …